Advertisement

The Role of Radiotherapy in Breast Cancer Management

  • Mutlay Sayan
  • Ruth HeimannEmail author
Chapter

Abstract

The X-rays were discovered in 1895 and the therapeutic effects were soon recognized. The first therapeutic use was in the early 1896 in a patient with recurrent carcinoma of the breast. Despite the technical limitations of the early equipment, tumor shrinkage and at times complete elimination of the tumor were noticed. However, the full potential of radiation therapy could not be achieved in those early days because of the limited knowledge regarding fractionation, treatment techniques, and uncertainties in how to calculate the tissue dose so as to deliver safe and effective doses of radiation. Much has changed in 120 years. Linear accelerators, megavoltage beam, and fast computers have revolutionized therapeutic radiation. The technological advances allow the delivery of the therapy more efficiently and accurately. Implementation of computer tomography-based three-dimensional treatment planning, intensity-modulated radiation therapy planning, and image-guided therapy are all resulting in decreased morbidity. Radiation is a major component in the treatment of all stages of breast cancer from ductal carcinoma in situ to metastatic disease. The radiation decreases the risk of locoregional recurrence, improves survival, and is used to palliate symptoms. It is indicated as adjuvant therapy after lumpectomy where it replaces mastectomy or postmastectomy. If the axilla is clinically negative and the sentinel node biopsy demonstrates low disease burden, radiation can substitute further axillary surgery resulting in decreased morbidity. Consultation with a radiation oncologist is an essential part of the multidisciplinary management of breast cancer.

Keywords

Breast cancer Radiotherapy Hypofractionation Intensity-modulated radiation therapy Partial breast irradiation Breast-conserving therapy Postmastectomy irradiation 

Abbreviations

CHF

Congestive heart failure

CT

Computed tomography

DCIS

Ductal carcinoma in situ

DIBH

Deep inspiration breath-hold

EORTC

European Organization for Research and Treatment of Cancer

IMNs

Internal mammary nodes

IMRT

Intensity-modulated radiation therapy

LINAC

Linear accelerator

MLC

Multileaf collimator

MRI

Magnetic resonance imaging

NIH

National Institutes of Health

NSABP

National Surgical Adjuvant Breast and Bowel Project

PET

Positron-emission tomography

US

Ultrasound

References

  1. 1.
    Moulin Dd. A short history of breast cancer. Boston: Martinus Nijhoff; 1983.CrossRefGoogle Scholar
  2. 2.
    Harsolia A, Kestin L, Grills I, Wallace M, Jolly S, Jones C, et al. Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68(5):1375–80.PubMedCrossRefGoogle Scholar
  3. 3.
    Pignol J, Olivotto I, Rakovitch E, Gardner S, Ackerman I, Sixel K, et al. Plenary 1. Int J Radiat Oncol Biol Phys 66(3):S1.Google Scholar
  4. 4.
    Woo TC, Pignol JP, Rakovitch E, Vu T, Hicks D, O’Brien P, et al. Body radiation exposure in breast cancer radiotherapy: impact of breast IMRT and virtual wedge compensation techniques. Int J Radiat Oncol Biol Phys. 2006;65(1):52–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Eng J Med. 2010;362(6):513–20.CrossRefGoogle Scholar
  6. 6.
    Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–94.PubMedCrossRefGoogle Scholar
  7. 7.
    MacDonald SM, Patel SA, Hickey S, Specht M, Isakoff SJ, Gadd M, et al. Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2013;86(3):484–90.PubMedCrossRefGoogle Scholar
  8. 8.
    Heimann R, Powers C, Halpem HJ, Michel AG, Ewing CA, Wyman B, et al. Breast preservation in stage I and II carcinoma of the breast. The University of Chicago experience. Cancer. 1996;78(8):1722–30.PubMedCrossRefGoogle Scholar
  9. 9.
    Lingos TI, Recht A, Vicini F, Abner A, Silver B, Harris JR. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1991;21(2):355–60.PubMedCrossRefGoogle Scholar
  10. 10.
    Cuzick J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clinic Oncol Off J Am Soc Clinic Oncol. 1994;12(3):447–53.CrossRefGoogle Scholar
  11. 11.
    Rutqvist LE, Lax I, Fornander T, Johansson H. Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys. 1992;22(5):887–96.PubMedCrossRefGoogle Scholar
  12. 12.
    Vallis KA, Pintilie M, Chong N, Holowaty E, Douglas PS, Kirkbride P, et al. Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. J Clinic Oncol Off J Am Soc Clinic Oncol. 2002;20(4):1036–42.CrossRefGoogle Scholar
  13. 13.
    Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005;97(6):419–24.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Pierce SM, Recht A, Lingos TI, Abner A, Vicini F, Silver B, et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys. 1992;23(5):915–23.PubMedCrossRefGoogle Scholar
  15. 15.
    Stewart JR, Fajardo LF, Gillette SM, Constine LS. Radiation injury to the heart. Int J Radiat Oncol Biol Phys. 1995;31(5):1205–11.PubMedCrossRefGoogle Scholar
  16. 16.
    Seddon B, Cook A, Gothard L, Salmon E, Latus K, Underwood SR, et al. Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2002;64(1):53–63.CrossRefGoogle Scholar
  17. 17.
    Taylor CW, Nisbet A, McGale P, Darby SC. Cardiac exposures in breast cancer radiotherapy: 1950s–1990s. Int J Radiat Oncol Biol Phys. 2007;69(5):1484–95.PubMedCrossRefGoogle Scholar
  18. 18.
    McGale P, Darby SC, Hall P, Adolfsson J, Bengtsson NO, Bennet AM, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2011;100(2):167–75.CrossRefGoogle Scholar
  19. 19.
    Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Eng J Med. 2013;368(11):987–98.CrossRefGoogle Scholar
  20. 20.
    Chen MH, Chuang ML, Bornstein BA, Gelman R, Harris JR, Manning WJ. Impact of respiratory maneuvers on cardiac volume within left-breast radiation portals. Circulation. 1997;96(10):3269–72.PubMedCrossRefGoogle Scholar
  21. 21.
    Lu HM, Cash E, Chen MH, Chin L, Manning WJ, Harris J, et al. Reduction of cardiac volume in left-breast treatment fields by respiratory maneuvers: a CT study. Int J Radiat Oncol Biol Phys. 2000;47(4):895–904.PubMedCrossRefGoogle Scholar
  22. 22.
    Sixel KE, Aznar MC, Ung YC. Deep inspiration breath hold to reduce irradiated heart volume in breast cancer patients. Int J Radiat Oncol Biol Phys. 2001;49(1):199–204.PubMedCrossRefGoogle Scholar
  23. 23.
    Warren LE, Miller CL, Horick N, Skolny MN, Jammallo LS, Sadek BT, et al. The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study. Int J Radiat Oncol Biol Phys. 2014;88(3):565–71.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Neugut AI, Weinberg MD, Ahsan H, Rescigno J. Carcinogenic effects of radiotherapy for breast cancer. Oncology (Williston Park, NY). 1999;13(9):1245–56; discussion 57, 61–5.Google Scholar
  26. 26.
    Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Eng J Med. 1992;326(12):781–5.CrossRefGoogle Scholar
  27. 27.
    Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2003;56(4):1038–45.PubMedCrossRefGoogle Scholar
  28. 28.
    Storm HH, Andersson M, Boice JD Jr, Blettner M, Stovall M, Mouridsen HT, et al. Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst. 1992;84(16):1245–50.PubMedCrossRefGoogle Scholar
  29. 29.
    Abdalla I, Thisted RA, Heimann R. The impact of contralateral breast cancer on the outcome of breast cancer patients treated by mastectomy. Cancer J (Sudbury, Mass). 2000;6(4):266–72.Google Scholar
  30. 30.
    Inskip PD, Stovall M, Flannery JT. Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst. 1994;86(13):983–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Neugut AI, Murray T, Santos J, Amols H, Hayes MK, Flannery JT, et al. Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer. 1994;73(6):1615–20.PubMedCrossRefGoogle Scholar
  32. 32.
    Taghian A, de Vathaire F, Terrier P, Le M, Auquier A, Mouriesse H, et al. Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys. 1991;21(2):361–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Eng J Med. 1992;326(26):1745–51.CrossRefGoogle Scholar
  34. 34.
    Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.PubMedCrossRefGoogle Scholar
  35. 35.
    Kirova YM, Gambotti L, De Rycke Y, Vilcoq JR, Asselain B, Fourquet A. Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. Int J Radiat Oncol Biol Phys. 2007;68(2):359–63.PubMedCrossRefGoogle Scholar
  36. 36.
    Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer. 1995;76(7):1197–200.PubMedCrossRefGoogle Scholar
  37. 37.
    Betsill WL Jr, Rosen PP, Lieberman PH, Robbins GF. Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA. 1978;239(18):1863–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.PubMedCrossRefGoogle Scholar
  39. 39.
    Frykberg ER, Bland KI. Overview of the biology and management of ductal carcinoma in situ of the breast. Cancer. 1994;74(1 Suppl):350–61.PubMedCrossRefGoogle Scholar
  40. 40.
    Hillner BE, Desch CE, Carlson RW, Smith TJ, Esserman L, Bear HD. Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast. J Clinic Oncol Off J Am Soc Clinic Oncol. 1996;14(1):70–7.CrossRefGoogle Scholar
  41. 41.
    Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clinic Oncol Off J Am Soc Clinic Oncol. 1998;16(2):441–52.CrossRefGoogle Scholar
  42. 42.
    Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer. 1995;75(6):1310–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999;86(3):429–38.PubMedCrossRefGoogle Scholar
  44. 44.
    Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478–88.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Fisher ER, Leeming R, Anderson S, Redmond C, Fisher B. Conservative management of intraductal carcinoma (DCIS) of the breast. Collaborating NSABP investigators. J Surg Oncol. 1991;47(3):139–47.PubMedCrossRefGoogle Scholar
  46. 46.
    Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853–a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clinic Oncol Off J Am Soc Clinic Oncol. 2006;24(21):3381–7.CrossRefGoogle Scholar
  47. 47.
    Omlin A, Amichetti M, Azria D, Cole BF, Fourneret P, Poortmans P, et al. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol. 2006;7(8):652–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Sahoo S, Recant WM, Jaskowiak N, Tong L, Heimann R. Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience. Breast J. 2005;11(4):242–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000.PubMedCrossRefGoogle Scholar
  50. 50.
    Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer. 1996;77(11):2267–74.PubMedCrossRefGoogle Scholar
  51. 51.
    Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Eng J Med. 1999;340(19):1455–61.CrossRefGoogle Scholar
  52. 52.
    Heimann R, Karrison T, Hellman S. Treatment of ductal carcinoma in situ. N Eng J Med. 1999;341(13):999–1000.Google Scholar
  53. 53.
    Macdonald HR, Silverstein MJ, Lee LA, Ye W, Sanghavi P, Holmes DR, et al. Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast. Am J Surg. 2006;192(4):420–2.PubMedCrossRefGoogle Scholar
  54. 54.
    Wong JS, Kaelin CM, Troyan SL, Gadd MA, Gelman R, Lester SC, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clinic Oncol Off J Am Soc Clinic Oncol. 2006;24(7):1031–6.CrossRefGoogle Scholar
  55. 55.
    McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clinic Oncol Off J Am Soc Clinic Oncol. 2015;33(7):709–15.CrossRefGoogle Scholar
  56. 56.
    Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clinic Oncol Off J Am Soc Clinic Oncol. 2009;27(32):5319–24.CrossRefGoogle Scholar
  57. 57.
    NIH Consensus Development Conference statement on the treatment of early-stage breast cancer. Oncology (Williston Park, NY). 1991;5(2):120–4.Google Scholar
  58. 58.
    Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Eng J Med. 2002;347(16):1227–32.CrossRefGoogle Scholar
  59. 59.
    van Dongen JA, Bartelink H, Fentiman IS, Lerut T, Mignolet F, Olthuis G, et al. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. J Natl Cancer Inst Monogr. 1992;11:15–8.Google Scholar
  60. 60.
    Blichert-Toft M, Rose C, Andersen JA, Overgaard M, Axelsson CK, Andersen KW, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr. 1992(11):19–25.Google Scholar
  61. 61.
    Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Eng J Med. 2002;347(16):1233–41.CrossRefGoogle Scholar
  62. 62.
    Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer. 2003;98(4):697–702.PubMedCrossRefGoogle Scholar
  63. 63.
    Arriagada R, Le MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clinic Oncol Off J Am Soc Clinic Oncol 1996;14(5):1558–64.Google Scholar
  64. 64.
    Hwang ES, Lichtensztajn DY, Gomez SL, Fowble B, Clarke CA. Survival after lumpectomy and mastectomy for early stage invasive breast cancer. Cancer. 2013;119(7):1402–11.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Farrow DC, Hunt WC, Samet JM. Geographic variation in the treatment of localized breast cancer. N Eng J Med. 1992;326(17):1097–101.CrossRefGoogle Scholar
  66. 66.
    Nattinger AB, Goodwin JS. Geographic and Hospital Variation in the Management of Older Women With Breast Cancer. Cancer Control J Moffitt Cancer Center. 1994;1(4):334–8.Google Scholar
  67. 67.
    Lazovich DA, White E, Thomas DB, Moe RE. Underutilization of breast-conserving surgery and radiation therapy among women with stage I or II breast cancer. JAMA. 1991;266(24):3433–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Lazovich D, Solomon CC, Thomas DB, Moe RE, White E. Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer. 1999;86(4):628–37.Google Scholar
  69. 69.
    Hiotis K, Ye W, Sposto R, Goldberg J, Mukhi V, Skinner K. The importance of location in determining breast conservation rates. Am J Surg. 2005;190(1):18–22.PubMedCrossRefGoogle Scholar
  70. 70.
    Hiotis K, Ye W, Sposto R, Skinner KA. Predictors of breast conservation therapy: size is not all that matters. Cancer. 2005;103(5):892–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Morrow M, Bucci C, Rademaker A. Medical contraindications are not a major factor in the underutilization of breast conserving therapy. J Am Coll Surg. 1998;186(3):269–74.PubMedCrossRefGoogle Scholar
  72. 72.
    Joslyn SA. Radiation therapy and patient age in the survival from early-stage breast cancer. Int J Radiat Oncol Biol Phys. 1999;44(4):821–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clinic Oncol Off J Am Soc Clinic Oncol. 2000;18(6):1220–9.CrossRefGoogle Scholar
  74. 74.
    Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N Eng J Med. 2007;356(23):2399–405.CrossRefGoogle Scholar
  75. 75.
    McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–35.PubMedCrossRefGoogle Scholar
  76. 76.
    Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer. 1985;56(5):979–90.PubMedCrossRefGoogle Scholar
  77. 77.
    Kurtz JM, Amalric R, Brandone H, Ayme Y, Jacquemier J, Pietra JC, et al. Local recurrence after breast-conserving surgery and radiotherapy. Frequency, time course, and prognosis. Cancer. 1989;63(10):1912–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Recht A, Silen W, Schnitt SJ, Connolly JL, Gelman RS, Rose MA, et al. Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1988;15(2):255–61.PubMedCrossRefGoogle Scholar
  79. 79.
    Winchester DP, Cox JD. Standards for breast-conservation treatment. CA Cancer J Clin. 1992;42(3):134–62.PubMedCrossRefGoogle Scholar
  80. 80.
    Winchester DP, Cox JD. Standards for diagnosis and management of invasive breast carcinoma. American College of Radiology. American College of Surgeons. College of American Pathologists. Society of Surgical Oncology. CA Cancer J Clin. 1998;48(2):83–107.PubMedCrossRefGoogle Scholar
  81. 81.
    Park CC, Mitsumori M, Nixon A, Recht A, Connolly J, Gelman R, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clinic Oncol Off J Am Soc Clinic Oncol. 2000;18(8):1668–75.CrossRefGoogle Scholar
  82. 82.
    Jones H, Antonini N, Colette L, Fourquet A, Hoogenraad WJ, Van den Bogaert W, et al. The impact of boost dose and margins on the local recurrence rate in breast conserving therapy: results from the EORTC boost-no boost trial. Int J Radiat Oncol Biol Phys. (2007);69(3):S2–S3.Google Scholar
  83. 83.
    Jones HA, Antonini N, Hart AA, Peterse JL, Horiot JC, Collin F, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clinic Oncol Off J Am Soc Clinic Oncol. 2009;27(30):4939–47.CrossRefGoogle Scholar
  84. 84.
    Mueller CB, Ames F, Anderson GD. Breast cancer in 3,558 women: age as a significant determinant in the rate of dying and causes of death. Surgery. 1978;83(2):123–32.PubMedGoogle Scholar
  85. 85.
    Yancik R, Ries LG, Yates JW. Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival. Cancer. 1989;63(5):976–81.PubMedCrossRefGoogle Scholar
  86. 86.
    Singh R, Hellman S, Heimann R. The natural history of breast carcinoma in the elderly: implications for screening and treatment. Cancer. 2004;100(9):1807–13.PubMedCrossRefGoogle Scholar
  87. 87.
    Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clinic Oncol Off J Am Soc Clinic Oncol. 2000;18(19):3360–9.CrossRefGoogle Scholar
  88. 88.
    Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clinic Oncol Off J Am Soc Clinic Oncol. 2006;24(16):2437–43.CrossRefGoogle Scholar
  89. 89.
    Turner BC, Harrold E, Matloff E, Smith T, Gumbs AA, Beinfield M, et al. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clinic Oncol Off J Am Soc Clinic Oncol. 1999;17(10):3017–24.CrossRefGoogle Scholar
  90. 90.
    Hellman S. The key and the lamppost. J Clinic Oncol Off J Am Soc Clinic Oncol. 1999;17(10):3007–8.CrossRefGoogle Scholar
  91. 91.
    Pierce LJ, Phillips KA, Griffith KA, Buys S, Gaffney DK, Moran MS, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010;121(2):389–98.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Liljegren G, Holmberg L, Bergh J, Lindgren A, Tabar L, Nordgren H, et al. 10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clinic Oncol Off J Am Soc Clinic Oncol. 1999;17(8):2326–33.CrossRefGoogle Scholar
  93. 93.
    Clark RM, Whelan T, Levine M, Roberts R, Willan A, McCulloch P, et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst. 1996;88(22):1659–64.PubMedCrossRefGoogle Scholar
  94. 94.
    Lim M, Bellon JR, Gelman R, Silver B, Recht A, Schnitt SJ, et al. A prospective study of conservative surgery without radiation therapy in select patients with Stage I breast cancer. Int J Radiat Oncol Biol Phys. 2006;65(4):1149–54.PubMedCrossRefGoogle Scholar
  95. 95.
    Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Eng J Med. 1995;333(22):1456–61.CrossRefGoogle Scholar
  96. 96.
    Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88(21):1529–42.PubMedCrossRefGoogle Scholar
  97. 97.
    Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clinic Oncol Off J Am Soc Clinic Oncol. 1996;14(7):1982–92.CrossRefGoogle Scholar
  98. 98.
    Carter DL, Marks LB, Bean JM, Broadwater G, Hussein A, Vredenburgh JJ, et al. Impact of consolidation radiotherapy in patients with advanced breast cancer treated with high-dose chemotherapy and autologous bone marrow rescue. J Clinic Oncol Off J Am Soc Clinic Oncol. 1999;17(3):887–93.CrossRefGoogle Scholar
  99. 99.
    Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clinic Oncol Off J Am Soc Clinic Oncol. 1998;16(8):2672–85.CrossRefGoogle Scholar
  100. 100.
    McCormick B, Begg CB, Norton L, Yao TJ, Kinne D. Timing of radiotherapy in the treatment of early-stage breast cancer. J Clinic Oncol Off J Am Soc Clinic Oncol. 1993;11(1):191–3.CrossRefGoogle Scholar
  101. 101.
    Heimann R, Powers C, Fleming G, Halpern HJ, Rubin SJ, Ewing C, et al. Does the sequencing of radiotherapy and chemotherapy affect the outcome in earlystage breast cancer: a continuing question. Int J Radiat Oncol Biol Phys 30:243.Google Scholar
  102. 102.
    Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Eng J Med. 1996;334(21):1356–61.CrossRefGoogle Scholar
  103. 103.
    Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. N Eng J Med. 2015;373(4):307–16.CrossRefGoogle Scholar
  104. 104.
    Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Eng J Med. 2015;373(4):317–27.CrossRefGoogle Scholar
  105. 105.
    Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Eng J Med. 1985;312(11):674–81.CrossRefGoogle Scholar
  106. 106.
    Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.PubMedCrossRefGoogle Scholar
  107. 107.
    Jagsi R, Chadha M, Moni J, Ballman K, Laurie F, Buchholz TA, et al. Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clinic Oncol Off J Am Soc Clinic Oncol. 2014;32(32):3600–6.CrossRefGoogle Scholar
  108. 108.
    Heimann R, Hellman S. Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J Clinic Oncol Off J Am Soc Clinic Oncol. 2000;18(3):591–9.CrossRefGoogle Scholar
  109. 109.
    Sugg SL, Ferguson DJ, Posner MC, Heimann R. Should internal mammary nodes be sampled in the sentinel lymph node era? Ann Surg Oncol. 2000;7(3):188–92.PubMedCrossRefGoogle Scholar
  110. 110.
    Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97(2):116–26.PubMedCrossRefGoogle Scholar
  111. 111.
    Recht A, Gray R, Davidson NE, Fowble BL, Solin LJ, Cummings FJ, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clinic Oncol Off J Am Soc Clinic Oncol. 1999;17(6):1689–700.CrossRefGoogle Scholar
  112. 112.
    Arriagada R, Rutqvist LE, Mattsson A, Kramar A, Rotstein S. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clinic Oncol Off J Am Soc Clinic Oncol. 1995;13(12):2869–78.CrossRefGoogle Scholar
  113. 113.
    Effects of Radiotherapy and Surgery in Early Breast. Cancer—an overview of the randomized trials. N Engl J Med. 1995;333(22):1444–56.CrossRefGoogle Scholar
  114. 114.
    Correa CR, Litt HI, Hwang WT, Ferrari VA, Solin LJ, Harris EE. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clinic Oncol Off J Am Soc Clinic Oncol. 2007;25(21):3031–7.CrossRefGoogle Scholar
  115. 115.
    Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clinic Oncol Off J Am Soc Clinic Oncol. 2006;24(15):2268–75.CrossRefGoogle Scholar
  116. 116.
    Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353(9165):1641–8.PubMedCrossRefGoogle Scholar
  117. 117.
    Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2007;82(3):247–53.CrossRefGoogle Scholar
  118. 118.
    Hellman S. Stopping metastases at their source. N Eng J Med. 1997;337(14):996–7.CrossRefGoogle Scholar
  119. 119.
    Hennequin C, Bossard N, Servagi-Vernat S, Maingon P, Dubois JB, Datchary J, et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2013;86(5):860–6.PubMedCrossRefGoogle Scholar
  120. 120.
    Salvadori B, Marubini E, Miceli R, Conti AR, Cusumano F, Andreola S, et al. Reoperation for locally recurrent breast cancer in patients previously treated with conservative surgery. Br J Surg. 1999;86(1):84–7.PubMedCrossRefGoogle Scholar
  121. 121.
    Halverson KJ, Perez CA, Kuske RR, Garcia DM, Simpson JR, Fineberg B. Isolated local-regional recurrence of breast cancer following mastectomy: radiotherapeutic management. Int J Radiat Oncol Biol Phys. 1990;19(4):851–8.PubMedCrossRefGoogle Scholar
  122. 122.
    Slavin SA, Love SM, Goldwyn RM. Recurrent breast cancer following immediate reconstruction with myocutaneous flaps. Plast Reconstr Surg. 1994;93(6):1191–204; discussion 205-7.Google Scholar
  123. 123.
    Ryu J, Yahalom J, Shank B, Chaglassian TA, McCormick B. Radiation therapy after breast augmentation or reconstruction in early or recurrent breast cancer. Cancer. 1990;66(5):844–7.PubMedCrossRefGoogle Scholar
  124. 124.
    Spanos WJ Jr, Montague ED, Fletcher GH. Late complications of radiation only for advanced breast cancer. Int J Radiat Oncol Biol Phys. 1980;6(11):1473–6.PubMedCrossRefGoogle Scholar
  125. 125.
    Touboul E, Lefranc JP, Blondon J, Ozsahin M, Mauban S, Schwartz LH, et al. Multidisciplinary treatment approach to locally advanced non-inflammatory breast cancer using chemotherapy and radiotherapy with or without surgery. Radiother Oncol J Eur Soc Ther Radiol Oncol. 1992;25(3):167–75.CrossRefGoogle Scholar
  126. 126.
    Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer. 1994;74(1 Suppl):416–23.PubMedCrossRefGoogle Scholar
  127. 127.
    Perez CA, Graham ML, Taylor ME, Levy JF, Mortimer JE, Philpott GW, et al. Management of locally advanced carcinoma of the breast. I. Noninflammatory. Cancer. 1994;74(1 Suppl):453–65.PubMedCrossRefGoogle Scholar
  128. 128.
    Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, et al. Trends for inflammatory breast cancer: is survival improving? Oncologist. 2007;12(8):904–12.PubMedCrossRefGoogle Scholar
  129. 129.
    Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97(13):966–75.PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    Masters GM, Heimann R, Skoog L. Concomitant chemoradiotherapy with vinorelbine and paclitaxel with filgrastim(G-CSF) support in patients with unresectable breast cancer. Breast Cancer Res Treat. 1997;46(75).Google Scholar
  131. 131.
    Formenti SC, Symmans WF, Volm M, Skinner K, Cohen D, Spicer D, et al. Concurrent paclitaxel and radiation therapy for breast cancer. Seminars Radiat Oncol. 1999;9(2 Suppl 1):34–42.Google Scholar
  132. 132.
    Kao J, Conzen SD, Jaskowiak NT, Song DH, Recant W, Singh R, et al. Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys. 2005;61(4):1045–53.PubMedCrossRefGoogle Scholar
  133. 133.
    Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM, et al. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat. 2012;134(2):495–510.PubMedPubMedCentralCrossRefGoogle Scholar
  134. 134.
    Fields RC, Jeffe DB, Trinkaus K, Zhang Q, Arthur C, Aft R, et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol. 2007;14(12):3345–51.PubMedCrossRefGoogle Scholar
  135. 135.
    Harris E, Barry M, Kell MR. Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann Surg Oncol. 2013;20(9):2828–34.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of Radiation OncologyUniversity of Vermont Medical CenterBurlingtonUSA

Personalised recommendations